Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Caterina Senesi"'
Autor:
Andrea Castellucci, Emanuela Pepponi, Annalisa Bertellini, Caterina Senesi, Margherita Bettini, Cecilia Botti, Salvatore Martellucci, Pasquale Malara, Silvia Delmonte, Francesco Maria Crocetta, Martina Fornaciari, Francesca Lusetti, Giovanni Bianchin, Angelo Ghidini
Publikováno v:
Frontiers in Neurology, Vol 11 (2021)
We describe a rare case of posterior semicircular canal (PSC) fibrosis following acute labyrinthine ischemia in the territory supplied by the common cochlear artery (CCA) and review the relevant literature. A 71-year-old man with multiple vascular ri
Externí odkaz:
https://doaj.org/article/cf9561b1d46f419088ee55179df5b5b1
Publikováno v:
Clinical Management Issues, Vol 6, Iss 2, Pp 51-57 (2012)
The recent improvements in multiple sclerosis therapy have lead to consequent improvements in its prognosis: however, it still remains a chronic and unpredictable disease. The moment of the diagnosis is the starting point of a durable relationship be
Externí odkaz:
https://doaj.org/article/5bce9b403f3c4cb6b87e6e08b94f5cd9
Autor:
Eleonora Baldi, Sara Montepietra, Franco Granella, Claudia Mauri, Paolo Immovilli, Mario Santangelo, Erica Curti, Diana Ferraro, Caterina Senesi, Maria Rosaria Tola, Anna Maria Simone, Francesca Vitetta, Angelica Guareschi, Luisa Caniatti, Giorgia Adani, W. Neri, Ilaria Pesci, Patrizia Sola, Enrico Montanari, Luisa Motti, Silvia Strumia
Publikováno v:
Neurological Sciences. 38:1453-1459
The frequency of definitive childlessness in women with multiple sclerosis (MS) may be higher than in the general population. MS may also affect decisions on the delivery procedure and on breast-feeding issues. Aim of the study was to assess the freq
Autor:
Luisa Motti, Caterina Senesi, Franco Granella, Maria Rosaria Tola, Sara Montepietra, Eleonora Baldi, Paolo Immovilli
Publikováno v:
Journal of Clinical Case Reports. 5
Background: Many patients with relapsing-remitting MS (RRMS) show a suboptimal response to first-line disease-modifying drugs. In these patients treatment with natalizumab is highly effective, however its use has been limited due to safety concerns.